AKTS (Aktis Oncology) Current Deferred Revenue: $18.96 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $25.00
! 1 Warning Sign
View Full Analysis

What is Aktis Oncology Current Deferred Revenue?

Aktis Oncology AKTS +5.06% 9 Current Deferred Revenue is $18.96 Mil as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Aktis Oncology's current deferred revenue for the quarter that ended in Mar. 2026 was $18.96 Mil.

Aktis Oncology Current Deferred Revenue Related Terms

Aktis Oncology Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Current Deferred Revenue Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
0.00 0.00 9.28 18.66

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only 0.00 16.08 18.66 18.96 0.00
AKTS
9GF Score
Aktis Oncology Inc AKTS
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $18.96 Mil mean?
Aktis Oncology (AKTS) has a Current Deferred Revenue of $18.96 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Current Deferred Revenue too high?
Aktis Oncology's current Current Deferred Revenue is $18.96 Mil. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Current Deferred Revenue compare to ABSI and MNKD?
Aktis Oncology's Current Deferred Revenue of $18.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Current Deferred Revenue is $18.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Current Deferred Revenue of $18.96 Mil. The current Current Deferred Revenue is $18.96 Mil. Aktis Oncology's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Current Deferred Revenue is $18.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price